<DOC>
	<DOCNO>NCT00002535</DOCNO>
	<brief_summary>RATIONALE : Biological therapy use different way stimulate immune system stop tumor cell grow . Combining biological therapy indomethacin cyclophosphamide may kill tumor cell . PURPOSE : Phase II trial compare effectiveness indomethacin biological therapy without cyclophosphamide treat patient advanced melanoma respond previous therapy .</brief_summary>
	<brief_title>Indomethacin Plus Biological Therapy Treating Patients With Advanced Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether indomethacin give prior tumor removal increase number tumor infiltrate lymphocyte ( TIL ) obtain tumor specimen patient advance melanoma . II . Determine efficacy administer concurrent indomethacin maximize immune effector cell function situ interleukin-2/TIL therapy patient . III . Determine relationship phenotypic character TIL ( generated culture patient 's tumor ) response therapy . IV . Correlate lytic activity lymphokine production TIL ( generated culture patient 's tumor ) clinical response therapy . V. Generate use lymphokine-activated killer ( LAK ) cell patient TIL available therapy evaluate LAK cell manner TIL . OUTLINE : Patients resectable tumor adequate generation TIL treat Regimen A ; unresectable tumor insufficient TIL treat Regimen B . The following acronym use : CTX Cyclophosphamide , NSC-26271 IL-2 Interleukin-2 ( Cetus ) , NSC-373364 LAK Lymphokine-Activated Killer Cells TIL Tumor Infiltrating Lymphocytes Regimen A : Prostaglandin Inhibition Therapy plus Biological Response Modifier Therapy . Indomethacin ; plus CTX ; IL-2-activated TIL ; IL-2 . Regimen B : Prostaglandin Inhibition Therapy plus Biological Response Modifier Therapy . Indomethacin ; plus IL-2-activated LAK ; IL-2 . PROJECTED ACCRUAL : Up 30 patient accrue 3 year . If 0 first 10 patient , 1 first 15 patient , 2 first 20 patient respond , accrual cease .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically document melanoma metastatic unresectable unresponsive conventional chemotherapy and/or radiotherapy Measurable evaluable disease require Measurable disease define bidimensionally measurable lesion physical exam , xray , MRI Evaluable disease define : Unidimensionally measurable lesion xray , scan , photograph Disease assessable serial chemistry , tumor marker , nonspecific scan Disease assessable functional manifestation ( e.g. , change performance status , 10 % great change weight ) Previously irradiate lesion subsequent disease progression document Boneonly lesion may consider evaluable ( lytic lesion xray bone scan follow ) No metastases CT MRI involve 50 % liver No uncontrolled untreated CNS metastases PATIENT CHARACTERISTICS : Age : Over 16 Performance status : ECOG 0 1 Life expectancy : At least 3 month Hematopoietic : ( unless tumor involvement bone marrow spleen document ) WBC least 3,500/mm3 Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 11.5 g/dL No significant hematologic abnormality Hepatic : ( unless tumor involvement liver document ) Bilirubin great 1.6 mg/dL SGOT great 150 U/L PT least 1.5 time control PTT le 1.5 time control Renal : ( unless tumor involvement kidney document ) Creatinine great 2.0 mg/dL Creatinine clearance least 50 mL/min Calcium great 12 mg/dL No symptomatic hypercalcemia Cardiovascular : No myocardial infarction within 6 month No congestive heart failure No edema No hypotension hypertension No coronary artery disease No history arrhythmia No contraindication use pressor agent Pulmonary : FEV1 least 65 % predict Other : No significant organ dysfunction No uncontrolled bacterial , viral , fungal infection No active peptic duodenal ulcer No psychiatric seizure disorder No prior solid organ allograft HIV hepatitis B surface antigen seronegative within 6 month study entry No second malignancy within 5 year except : Inactive nonmelanomatous skin cancer Carcinoma situ cervix No serious illness would limit survival less 2 year Negative pregnancy test PRIOR CONCURRENT THERAPY : Biologic therapy : More 4 week since immunotherapy Chemotherapy : Prior anthracyclines allow provide symptomatic heart disease present More 4 week since chemotherapy ( least 2 week , recovery , disease progression document ) More 6 week since nitrosoureas , melphalan , mitomycin Endocrine therapy : More 1 week since corticosteroid ( except physiological dos respiratory ailment adrenal insufficiency ) Radiotherapy : More 4 week since radiotherapy ( least 2 week , recovery , disease progression document ) Surgery : More 3 week since major surgery ( exclude surgery tumor collection )</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2000</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>